English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid

MPS-Authors
/persons/resource/persons50519

Schjeide,  B. M.
Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

/persons/resource/persons50098

Bertram,  L.
Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

Giedraitis.pdf
(Any fulltext), 232KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Giedraitis, V., Glaser, A., Sarajarvi, T., Brundin, R., Gunnarsson, M. D., Schjeide, B. M., et al. (2010). CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neuroscience Letters, 469(2), 265-267. doi:10.1016/j.neulett.2009.12.011.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0010-7C0E-3
Abstract
Recently, the P86L alteration in CALHM1 (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid-beta (A beta) levels in conditioned media from cultured cells. Therefore, we hypothesized that CALHM1 P86L may modulate A beta or tau levels in cerebrospinal fluid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included for CSF analysis and CALHM1 genotyping. No significant differences in CSF levels of A beta 42, tau or phospho-tau were found across the various CALHM1 genotypes. In conclusion, we found no evidence that CALHM1 P86L is associated with altered CSF levels of the investigated AD biomarkers.